tiprankstipranks
Biogen (BIIB)
NASDAQ:BIIB

Biogen (BIIB) Technical Analysis

4,367 Followers

Technical Sentiment

Overall Consensus
Sell
6Bullish
6Neutral
10Bearish
Technical Analysis Consensus
Neutral
2Bullish
6Neutral
2Bearish
Moving Average Consensus
Sell
4Bullish
0Neutral
8Bearish
Biogen’s (BIIB) Moving Averages Convergence Divergence (MACD) indicator is 1.88, suggesting Biogen is a Buy.
Biogen’s (BIIB) 20-Day exponential moving average is 220.21, while Biogen’s (BIIB) share price is $220.07, making it a Sell.
Biogen’s (BIIB) 50-Day exponential moving average is 218.40, while Biogen’s (BIIB) share price is $220.07, making it a Buy.

Biogen (BIIB) Pivot Points

May 31, 2024, 10:57 AM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
204.96
207.64
211.03
213.71
217.10
219.78
223.17
Fibonacci
207.64
209.96
211.39
213.71
216.03
217.46
219.78
Pivot points are a technical analysis tool used by traders to identify potential support and resistance levels in financial markets. Pivot points are calculated based on the previous day's high, low, and close prices, and are used to help traders identify levels at which the price may reverse or continue to trend.

Biogen (BIIB) Moving Averages

May 31, 2024, 10:57 AM
Period
Simple
Exponential
MA5
217.82Buy
219.28Buy
MA10
223.42Sell
221.00Sell
MA20
222.85Sell
220.21Sell
MA50
212.87Buy
218.40Buy
MA100
223.63Sell
223.85Sell
MA200
237.53Sell
238.79Sell
Biogen’s (BIIB) 10-Day exponential moving average is 221.00, while Biogen’s (BIIB) share price is $220.07, making it a Sell.
Biogen’s (BIIB) 100-Day exponential moving average is 223.85, while Biogen’s (BIIB) share price is $220.07, making it a Sell.
Biogen’s (BIIB) stock price is $220.07 and Biogen’s (BIIB) 50-day simple moving average is 212.87, creating a Buy signal.
Biogen’s (BIIB) stock price is $220.07 and Biogen’s (BIIB) 100-day simple moving average is 223.63, creating a Sell signal.
Biogen’s (BIIB) stock price is $220.07 and Biogen’s (BIIB) 200-day simple moving average is 237.53, creating a Sell signal.

Biogen (BIIB) Technical Indicators

May 31, 2024, 10:57 AM
Name
Value
Implied Action
RSI (14)
51.15
Neutral
STOCH (9,6)
25.55
Neutral
STOCHRSI (14)
22.80
Neutral
MACD (12,26)
1.88
Buy
ADX (14)
25.70
Neutral
Williams %R
-63.34
Buy
CCI (14)
-64.45
Neutral
ATR (14)
5.67
-
Ultimate Oscillator
55.17
Neutral
ROC
-1.20
Sell
Biogen’s (BIIB) Relative Strength Index (RSI) is 51.15, creating a Neutral signal.
Biogen’s (BIIB) Trend Strength Indicator (ADX) is 25.70, creating a Neutral signal.
Biogen’s (BIIB) Commodity Channel Index (CCI) is -64.45, creating a Neutral signal.
Biogen’s (BIIB) Price Rate of Change (ROC) is -1.20, creating a Sell signal.

FAQ

Is BIIB a Buy, Hold, or Sell?
Based on BIIB’s technical indicators, BIIB is a Sell.
    What is BIIB’s RSI (14)?
    BIIB’s RSI (14) is 51.15, which suggests BIIB is a Neutral.
      What is BIIB’s MACD?
      BIIB’s MACD is 1.88, which suggests BIIB is a Buy.
        What is BIIB’s 5-day moving average?
        BIIB’s 5-day moving average is 217.82, which suggests BIIB is a Buy.
          What is BIIB’s 20-day moving average?
          BIIB 20-day moving average is 222.85, which suggests BIIB is a Sell.
            What is BIIB’s 50-day moving average?
            BIIB’s 50-day moving average is 212.87, which suggests BIIB is a Buy.
              What is BIIB’s 200-day moving average?
              BIIB’s 200-day moving average is 237.53, which suggests BIIB is a Sell.
                What is BIIB’s Williams % R (14)?
                BIIB’s Williams % R (14) is -63.34, which suggests BIIB is a Buy.
                  What is BIIB’s CCI (14)?
                  BIIB’s CCI (14) is -64.45, which suggests BIIB is a Neutral.
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis